Gold Standard
Regenerative
Stem cell therapy for shoulder pain is explored by patients dealing with chronic injuries, rotator cuff damage, or joint degeneration. Candidacy is determined through medical evaluation, including imaging and clinical history. Not all patients qualify.
This approach is typically explored by individuals experiencing:
Many patients begin exploring regenerative options when trying to avoid or delay surgical intervention.
For general background on orthopedic applications of regenerative medicine, see Mayo Clinic and Cleveland Clinic.
Stem cell therapy is not suitable for every condition. This approach may not be recommended for:
A proper evaluation is required to determine candidacy.
Medical history and imaging (MRI or X-ray) are reviewed to assess tissue damage and joint condition.
If appropriate, a treatment plan is developed based on the severity of the injury and patient-specific factors.
Regenerative cells are administered in a clinical setting. The exact protocol varies depending on the case.
Patients are monitored over time to evaluate mobility, pain levels, and functional improvements.
Stem cell therapy may be explored for:
For more on shoulder conditions and standard treatments, refer to the American Academy of Orthopaedic Surgeons.
Not sure whether this applies to your case? Candidacy is determined by medical review of your history and imaging, not by a form. The consultation is complimentary.
See If You QualifySome individuals explore treatment options outside the United States due to:
This approach is part of a broader category known as medical travel.
Patients exploring regenerative therapy for shoulder conditions often seek improvements in:
Addressing chronic shoulder pain that limits quality of life
Restoring flexibility and mobility in the shoulder joint
Returning to daily activities and normal mobility
Outcomes vary depending on condition severity, age, and overall health.
Research into regenerative medicine is ongoing. For additional context, see the National Institutes of Health.
All medical procedures involve risks and limitations.
Stem cell therapy is considered an evolving area of medicine, and results are not guaranteed. Patients should undergo proper evaluation and understand all considerations before proceeding.
Regulatory information can be reviewed through the U.S. Food and Drug Administration.
Regenerative treatment for shoulder and rotator cuff conditions is investigational and is not approved by the U.S. Food and Drug Administration for this use. Research in the shoulder is at an earlier stage than the corresponding work in the knee, so it is worth understanding what it does and does not currently show.
A 2025 systematic review in JSES Reviews, Reports, and Techniques examined mesenchymal stem cells used alongside rotator cuff repair surgery across five studies and 228 patients. Adverse events were somewhat more frequent in treated patients, but the difference was not statistically significant and all of them resolved, with no difference between groups in severity or recovery time. In a separate randomised trial, side effects were limited to mild injection site pain lasting two to three weeks, with no lasting complications.
A 2022 randomised, double-blinded, placebo-controlled trial in Scientific Reports followed 23 patients with partial tears of the supraspinatus tendon for two years. Pain improved across every group in the study, including the group that received saline, and the difference between them was not statistically significant. In the 2025 review, adding cells to surgical repair likewise produced no significant difference in pain, function or range of motion compared with repair alone. The one favourable finding was a lower retear rate, 13 percent against 56 percent at ten years, in a single study.
The review's authors rated the overall quality of the evidence as very low. They noted wide variation between studies, sample sizes small enough that a real effect could be missed, and described the literature as "still preliminary." That caution applies in both directions: these trials are not large enough to establish a benefit, and they are not large enough to rule one out. The retear finding rests on the same limited evidence and is best read as a question worth studying rather than a settled result.
What that means in practice: the safety signal so far is reassuring, effectiveness in the shoulder is not established, and no honest account of this research can promise that a shoulder will improve. Whether any of it is appropriate for you is a decision for a physician who has reviewed your imaging and history, and for some shoulders the right answer will be surgery or conservative care instead.
Sources: A randomized controlled trial of stem cell injection for tendon tear, Scientific Reports, 2022. The role of injections of mesenchymal stem cells as an augmentation tool in rotator cuff repair: a systematic review, JSES Reviews, Reports, and Techniques, 2025.
The procedure itself is typically completed in a single visit, though the overall process varies depending on evaluation and follow-up.
Recovery timelines vary. Some patients resume normal activities relatively quickly, depending on the protocol and condition.
Costs vary based on treatment complexity and individual needs. Evaluation is required before any estimate is provided.
Some regenerative treatments are regulated differently. Patients should understand the distinction between approved and investigational therapies.
Candidacy depends on imaging, medical history, and the nature of the shoulder condition. Not all patients qualify.
If you are dealing with shoulder pain, rotator cuff injury, or limited mobility, the first step is determining whether you qualify for treatment. Candidacy is based on medical evaluation, not assumptions.
Start Your Evaluation →Medically reviewed by Dr. Karla Chavira, MD, Regenerative Medicine Physician and CEO of CMCells (Cédula Profesional on file).
Last reviewed: July 2026